Baxter Healthcare Patent-Cliff Exposure & CMS Drug Spending Portfolio
Baxter Healthcare (US): 11 reconciled FDA prescription therapies, $2.4M 2024 CMS Part D & Medicaid spend, and 28 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 11 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $2.4M |
| 2024 Medicare Part D Spend | $690K |
| 2024 Medicaid Spend | $1.8M |
| California HCAI SB 17 Filings | 28 WAC filings (max 25.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Baxter International across sibling Meru public-data platforms.